Molecular Partners AG (id:13143 MOLN)
4.82 CHF
Opening hours: 09:00 - 17:20 (Central European Standard Time: 11/22/2024 2:59:56 AM)
Exchange closed, opens in 6 hours
About Molecular Partners AG
Market Capitalization 178.84M
Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
| Headquarters (address) |
Wagistrasse 14 Schlieren 8952 Switzerland |
| Phone | 41 44 755 77 00 |
| Website | https://www.molecularpartners.com |
| Employees | 167 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | MOLN |
| Exchange | Swiss Stock Exchange |
| Currency | CHF |
| 52 week range | 3.10 - 9.50 |
| Market Capitalization | 178.84M |
| P/E trailing | 1.75 |
| P/E forward | -2.42 |
| Price/Sale | 29.80 |
| Price/Book | 1.16 |
| Beta | 0.537 |
| EPS | -1.89 |
| EPS Switzerland (ID:153, base:185) | 29.31 |